Medtronic‘s (NYSE:MDT) Resolute Onyx 2.0mm drug-eluting stent met its primary endpoint of target lesion failure at 1 year for the treatment of coronary artery disease in extra-small vessels, according to data from the Resolute Onyx 2.0mm trial.
The trial enrolled 101 patients with extra-small vessel sizes ranging from 2 millimeters to 2.25 millimeters. Patients treated with the Resolute Onyx 2.0 mm stent had significantly lower rates of target lesion failure at 1 year compared to a pre-determined performance goal.
Get the full story at our sister site, Drug Delivery Business News.
The post EuroPCR Roundup: Medtronic’s Resolute Onyx meets primary endpoint in small-vessel trial appeared first on MassDevice.